news
Tislelizumab reduces risk of death by 30 percent in oesophageal cancer trial
In a Phase III trial, Novartis’ investigational checkpoint inhibitor tislelizumab improved overall survival in patients with oesophageal squamous cell carcinoma.
List view / Grid view
Antibiotics
news
EU to support novel antibiotics with €20 million funding
BioVersys will receive €20 million in funding to support its development of new treatments for antimicrobial resistant infections.
news
Novel HIV vaccine approach shows promise in “landmark” first-in-human trial
The vaccine was able to target the desired immune cells and could become the first stage of a multi-step vaccine strategy to combat HIV and various other viral diseases.
news
Azithromycin and doxycycline of no benefit to COVID-19 patients, finds analysis
Trial finds neither azithromycin nor doxycycline meaningfully improve recovery times or reduce risk of hospitalisation in non-hospitalised COVID-19 patients.
news
Computational approach shows antibiotic resistance may spread more easily than expected
A novel algorithm shows that there is a robust network for transferring plasmids between bacteria which may be causing the rapid spread of antibiotic resistance.
news
Antibiotics market set to generate revenue of $58,800 million by 2027
A new report has predicted that the global antibiotics market will grow at a CAGR of four percent from 2020-2027.
news
Optimised formulation of gentamicin could reduce hearing loss
Analysing the components of gentamicin, researchers have developed a new formulation for the antibiotic that does not cause deafness.
news
Novel antibiotic shows promise in Phase II C. difficile study
Ibezapolstat cured all 10 patients of their Clostridioides difficile infections and prevented recurrence for at least 30 days.
news
Oral antibiotics effective at killing P. aeruginosa in cystic fibrosis patients
A clinical trial has shown that antibiotics administered orally are just as effective at killing Pseudomonas aeruginosa in cystic fibrosis patients as intravenous antibiotics.
news
Sandoz and Austrian government to invest in European antibiotic manufacturing
Sandoz plans to invest €150 million and the Austrian government €50 million into integrated antibiotic manufacturing operations at Kundl.
news
UK’s SARS-CoV-2 vaccine candidate is safe and induces antibody and T cell response
Data released from the Phase I/II trial of the ChAdOx1 COVID-19 vaccine candidate suggests it elicits an immune response with no adverse effects.
![Novartis logo Novartis building in Stein, Switzerland [Credit: Taljat David shutterstock.com]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/novartis-image-300x278.jpg)
![Novartis logo Novartis building in Stein, Switzerland [Credit: Taljat David shutterstock.com]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/novartis-image-scaled-e1594985022657.jpg)
news
Novartis launches not-for-profit COVID-19 medications portfolio
The portfolio will be offered to low- and lower-middle-income countries to help financially strained healthcare systems care for COVID-19 patients.
news
Global antimicrobial resistance fund to support development of innovative antibiotics
The fund has already raised $1 billion to support clinical research of novel antibiotics and intends to bring up to four new antibiotics to market by 2030.
news
UK launches scheme to encourage development of novel antibiotics
The NHS is offering two contracts to pay pharma companies at the start of their research into antibiotics, to promote the development of new antimicrobials.
news
WHO stresses need for new treatments to reduce antimicrobial resistance
Following a record level of data collated by WHO, the organisation has emphasised that new antibiotics need to be developed to tackle the rise of global antimicrobial resistance.